CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Prostate cancer statistics
Prostate cancer is the most common cancer among Canadian men (excluding non-melanoma skin cancers). It is the third leading cause of death from cancer in men in Canada.
To provide the most current cancer statistics, researchers use statistical methods to estimate the number of new cancer cases and deaths until actual data become available.
Incidence and mortality
Incidence is the total number of new cases of cancer. Mortality is the number of deaths due to cancer.
It is estimated that in 2020:
- 23,300 men will be diagnosed with prostate cancer. This represents 20% of all new cancer cases in men in 2020.
- 4,200 men will die from prostate cancer. This represents 10% of all cancer deaths in men in 2020.
- On average, 64 Canadian men will be diagnosed with prostate cancer every day.
- On average, 11 Canadian men will die from prostate cancer every day.
5-year net survival (estimates for 2012–2014)
Trends in prostate cancer
In Canada, the incidence rate of prostate cancer peaked in 1993 and again in 2001. Each of these peaks was followed by a decline. The decline has been particularly steep since 2011. The patterns in prostate cancer incidence largely mirror screening activity using the prostate-specific antigen (PSA) test.
The death rate for prostate cancer has been declining since 1994. The decline likely reflects improved treatment.
Chances (probability) of developing or dying from prostate cancer
It is estimated that about 1 in 9 Canadian men will develop prostate cancer during their lifetime and 1 in 29 will die from it.
For more information, go to Canadian Cancer Statistics publication.
A protein made by the prostate that is normally found in the semen and blood. Higher amounts of PSA may be found in the blood of men who have prostate cancer, benign prostatic hyperplasia (BPH) or inflammation of the prostate.
PSA can be used as a tumour marker. It is used to monitor a man’s response to treatment for prostate cancer, or to see if prostate cancer has come back (recurred) after treatment.